FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:1711-1712 December 6, 2001 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Tannock, I. F. PubMed Citation

To the Editor: In this issue of the Journal, Flanigan et al.¹ report the results of a randomized trial conducted by the Southwest Oncology Group (SWOG), which compared interferon alone with nephrectomy followed by interferon for the treatment of metastatic renal-cell cancer. There was a survival advantage in the surgery-plus-interferon group, as well as in all the risk strata. Similar results have been demonstrated in Europe by the Genito-Urinary Group of the European Organisation for Research and Treatment of Cancer, in a study with a similar protocol.² However, the issue of the most effective immunotherapeutic agent to use after nephrectomy . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Sato, E., Torigoe, T., Hirohashi, Y., Kitamura, H., Tanaka, T., Honma, I., Asanuma, H., Harada, K., Takasu, H., Masumori, N., Ito, N., Hasegawa, T., Tsukamoto, T., Sato, N. (2008). Identification of an Immunogenic CTL Epitope of HIFPH3 for Immunotherapy of Renal Cell Carcinoma. Clin. Cancer Res. 14: 6916-6923 [Abstract] [Full Text]  
• Jones, J., Libermann, T. A. (2007). Genomics of Renal Cell Cancer: The Biology Behind and the Therapy Ahead. Clin. Cancer Res. 13: 685s-692s [Abstract] [Full Text]  
• Pantuck, A. J., Belldegrun, A. S., Figlin, R. A. (2007). Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: Is It Still Imperative in the Era of Targeted Therapy?. Clin. Cancer Res. 13: 693s-696s [Abstract] [Full Text]  
• Wood, C. G. (2007). Multimodal Approaches in the Management of Locally Advanced and Metastatic Renal Cell Carcinoma: Combining Surgery and Systemic Therapies to Improve Patient Outcome. Clin. Cancer Res. 13: 697s-702s [Abstract] [Full Text]  
• Lam, J. S., Breda, A., Belldegrun, A. S., Figlin, R. A. (2006). Evolving Principles of Surgical Management and Prognostic Factors for Outcome in Renal Cell Carcinoma. JCO 24: 5565-5575 [Abstract] [Full Text]  
• Lam, J. S., Belldegrun, A. S., Figlin, R. A. (2004). Tissue Array-Based Predictions of Pathobiology, Prognosis, and Response to Treatment for Renal Cell Carcinoma Therapy. Clin. Cancer Res. 10: 6304S-6309S [Abstract] [Full Text]  
• Griffiths, T R L, Mellon, J K (2004). Evolving immunotherapeutic strategies in bladder and renal cancer. Postgrad. Med. J. 80: 320-327 [Abstract] [Full Text]  
• Pandha, H. (2004). Integrative Tumor Board: Metastatic Renal Cell Carcinoma. Integr Cancer Ther 3: 29-34  
• Zisman, A., Pantuck, A. J., Wieder, J., Chao, D. H., Dorey, F., Said, J. W., deKernion, J. B., Figlin, R. A., Belldegrun, A. S. (2002). Risk Group Assessment and Clinical Outcome Algorithm to Predict the Natural History of Patients With Surgically Resected Renal Cell Carcinoma. JCO 20: 4559-4566 [Abstract] [Full Text]  
• Tannock, I. F. (2001). Removing the Primary Tumor after the Cancer Has Spread. NEJM 345: 1699-1700 [Full Text]